Neuland Laboratories financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹642cr+119.2% on Q1 FY26
Net profit
₹148cr+962.4% on Q1 FY26
EBITDA margin
34.7%+23.0 pts on Q1 FY26
EPS
₹115.10+962.8% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue642293+119.2%
EBITDA22334.5+546.3%
EBITDA margin34.7%11.8%+23.0 pts
Profit before tax19817.6+1,026.0%
Net profit14813.9+962.4%
EPS₹115.10₹10.83+962.8%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹642 crNet profit₹148 crNet margin23.0%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
25,762————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
76.776.724087.645.4
19719713682.5122
25,882————
2,3722,0231,4771,5591,191
—+37.0%−5.2%+30.8%—
763574323463272
32.2%28.4%21.9%29.7%22.8%
665483258403219
498364260300164
21.0%18.0%17.6%19.3%13.7%
₹385.85₹282.16₹201.63₹232.61₹126.75
—+39.9%−13.3%+83.5%—
—347317261237
—−396−206−144−66.1
−49.4−49.4111118171
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

NEULANDLAB₹19,970.00

Neuland Laboratories Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABLAURUSLABSNHNATCOPHARMLALPATHLABSAILIFECOHANCEASTERDMMcap ₹25,762 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————25,762.3
- Cash, Equiv & ST Investments45.487.6239.676.776.7
+ Total Debt121.582.5136.0196.6196.6
Enterprise Value————25,882.2
Revenue1,191.21,558.61,476.82,023.02,371.8
Growth %, YoY—+30.8-5.2+37.0—
EBITDA271.8462.6323.3574.5762.9
Margin %22.8229.6821.8928.4032.17
EBIT219.1402.9257.7482.8664.8
Net Income163.5300.1260.1364.0497.8
Margin %13.7319.2517.6117.9920.99
EPS, Adj (current shares)126.75232.61201.63282.16385.85
Growth %, YoY—+83.5-13.3+39.9—
Cash from Operations237.2261.2317.4346.7—
Capital Expenditures-66.1-143.7-206.5-396.0—
Free Cash Flow171.1117.5110.9-49.4-49.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Neuland Laboratories financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Neuland Laboratories (NSE: NEULANDLAB) had a market capitalisation of ₹24,872 crore at the 29 October 2026 close (₹19,280.00 a share), a PE ratio of 50.0 on the last four quarters' profit and a price-to-book ratio of 13.27. In FY26 its consolidated net profit was ₹364 crore on revenue of ₹2,023 crore; in Q1 FY27 (April–June 2026) it was ₹148 crore, up 962.4% year on year. Its debt-to-equity ratio was 0.10 on 31 March 2026. Promoters held 32.26% of the shares on 30 September 2026.

Share price used
₹19,280.00 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Neuland Laboratories at a glance · consolidated

Market cap
₹24,872 Crat ₹19,280.00 · 29 Oct close
PE ratio (last 4 quarters)
50.068.3 on FY26 profit
Price to book (PB)
13.27book value ₹1,453.02 a share
ROE (FY26)
21.4%+2.9 pts vs FY25ROCE 24.5%
Debt to equity
0.10net cash ₹158 Cr
Promoter holding
32.26%−0.4 pts vs 30 Jun 202630 September 2026
Dividend yield
0.18%₹34 a share in 12 months
Net worth
₹1,874 Cr+22.9% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹49.4 Cr

Questions

What is the Neuland Laboratories PE ratio today?

Neuland Laboratories' PE ratio is 50.0 at the 29 October 2026 close (₹19,280.00 a share): a market capitalisation of ₹24,872 crore divided by consolidated net profit of ₹498 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹364 crore) it is 68.3.

What is the Neuland Laboratories net worth?

Neuland Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹1,874 crore on 31 March 2026, up 22.9% from ₹1,525 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹24,872 crore at the 29 October 2026 close.

What is the Neuland Laboratories book value per share?

Neuland Laboratories' book value per share was ₹1,453.02 on 31 March 2026: shareholders' equity of ₹1,874 crore divided by the 1.29 crore shares in issue, up 22.9% from ₹1,181.97 a year earlier. The share price at the 29 October 2026 close was ₹19,280.00.

What is the Neuland Laboratories PB ratio (price to book value)?

Neuland Laboratories' price-to-book (PB) ratio is 13.27 at the 29 October 2026 close: a market capitalisation of ₹24,872 crore divided by shareholders' equity (book value) of ₹1,874 crore on 31 March 2026. That is a book value of ₹1,453.02 per share against a share price of ₹19,280.00.

What is the Neuland Laboratories ROE and ROCE?

In FY26, Neuland Laboratories' return on equity (ROE) was 21.4% and its return on capital employed (ROCE) was 24.5%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 18.5% and ROCE 16.5%.

What is the Neuland Laboratories dividend yield?

Neuland Laboratories' dividend yield is 0.18% at the 29 October 2026 close: dividends of ₹34 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹19,280.00. They were ₹34 on 24 July 2026.

What is the Neuland Laboratories market cap?

Neuland Laboratories' market capitalisation was ₹24,872 crore at the 29 October 2026 close: 1.29 crore shares at ₹19,280.00 each.

Is Neuland Laboratories debt free?

No. Neuland Laboratories had borrowings of ₹197 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.10. Its cash and current investments were ₹355 crore, so it held net cash of ₹158 crore.

What is the Neuland Laboratories dividend in 2026 and its record date?

In 2026, Neuland Laboratories has declared one dividend: ₹34 with record date 24 July 2026.

What is the Neuland Laboratories debt to equity ratio?

Neuland Laboratories' debt-to-equity ratio was 0.10 on 31 March 2026: borrowings of ₹197 crore against total equity of ₹1,874 crore. A year earlier, on 31 March 2025, it was 0.09.

What is the Neuland Laboratories EPS?

Neuland Laboratories' basic earnings per share (EPS) were ₹283.71 in FY26, against ₹202.74 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹387.97.

When are the Neuland Laboratories next results?

Neuland Laboratories will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Neuland Laboratories promoter holding?

Promoters held 32.26% of Neuland Laboratories on 30 September 2026, down 0.36 percentage points from 32.62% the previous quarter and down 0.38 percentage points from 32.64% a year earlier, according to the shareholding pattern filed with NSE.

What is the Neuland Laboratories free cash flow?

In FY26, Neuland Laboratories generated ₹347 crore of cash from operations and spent ₹396 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹49.4 crore. In FY25 it was ₹111 crore.

What are the Neuland Laboratories latest quarterly results?

Neuland Laboratories' latest results are for Q1 FY27 (April–June 2026), filed on 5 August 2026: consolidated net profit ₹148 crore, up 962.4% from ₹13.9 crore in Q1 FY26; revenue from operations ₹642 crore, up 119.2% year on year.

What is the Neuland Laboratories shareholding pattern?

On 30 September 2026, Neuland Laboratories' shares were held by promoters 32.26%, foreign portfolio investors (FII/FPI) 21.93%, domestic institutions (DII) 16.26% (including mutual funds at 12.45%) and retail and other non-institutional investors 29.55%. Over the year, FII holding was up 1.33 percentage points from 20.60% and DII holding was up 2.72 percentage points from 13.54%.

What is the Neuland Laboratories revenue and profit in FY26?

In FY26 (April 2025–March 2026), Neuland Laboratories' consolidated net profit was ₹364 crore, up 39.9% from ₹260 crore in FY25, on revenue from operations of ₹2,023 crore (up 37.0%). Over three years, from FY23, net profit was up 122.6%.

How does the Neuland Laboratories PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Neuland Laboratories' PE ratio is 68.3, the third highest of the four: Divi's Labs 99.7, Laurus Labs 136.4 and Narayana Hrudayalaya 43.5, a peer average of 93.2. Each is the company's market capitalisation at that price divided by its FY26 net profit.

How does Neuland Laboratories compare with its peers?

On FY26 consolidated figures, against Divi's Labs, Laurus Labs and Narayana Hrudayalaya: Neuland Laboratories' operating margin of 23.9% is the second highest of the four (Divi's Labs 28.2%, Laurus Labs 19.1%, Narayana Hrudayalaya 14.8%; peer average 20.7%); its return on equity of 21.4% is the highest of the four (Divi's Labs 16.2%, Laurus Labs 18.2%, Narayana Hrudayalaya 19.7%; peer average 18.0%); its revenue growth over three years of 19.3% a year is the second highest of the four (Divi's Labs 10.8% a year, Laurus Labs 4.1% a year, Narayana Hrudayalaya 20.4% a year; peer average 11.8% a year).

Neuland Laboratories vs Divi's Labs: how do they compare?

In FY26, Neuland Laboratories earned net profit of ₹364 crore on revenue of ₹2,023 crore, against ₹2,568 crore on ₹10,560 crore for Divi's Labs. Neuland Laboratories' operating margin was 23.9% (Divi's Labs 28.2%) and its return on equity 21.4% (Divi's Labs 16.2%). At the 29 October 2026 close, Neuland Laboratories' market capitalisation was ₹24,872 crore against ₹2,56,096 crore for Divi's Labs, and its PE ratio on FY26 profit 68.3 against 99.7.

Where do these Neuland Laboratories figures come from?

From Neuland Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.